GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genomic Valley Biotech Ltd (BOM:539206) » Definitions » Shiller PE Ratio

Genomic Valley Biotech (BOM:539206) Shiller PE Ratio : 329.17 (As of May. 08, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Genomic Valley Biotech Shiller PE Ratio?

As of today (2025-05-08), Genomic Valley Biotech's current share price is ₹59.25. Genomic Valley Biotech's E10 for the quarter that ended in Dec. 2024 was ₹0.18. Genomic Valley Biotech's Shiller PE Ratio for today is 329.17.

The historical rank and industry rank for Genomic Valley Biotech's Shiller PE Ratio or its related term are showing as below:

BOM:539206' s Shiller PE Ratio Range Over the Past 10 Years
Min: 234.22   Med: 633.85   Max: 1006.25
Current: 332.02

During the past years, Genomic Valley Biotech's highest Shiller PE Ratio was 1006.25. The lowest was 234.22. And the median was 633.85.

BOM:539206's Shiller PE Ratio is ranked worse than
96.62% of 148 companies
in the Biotechnology industry
Industry Median: 33.805 vs BOM:539206: 332.02

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genomic Valley Biotech's adjusted earnings per share data for the three months ended in Dec. 2024 was ₹0.510. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₹0.18 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genomic Valley Biotech Shiller PE Ratio Historical Data

The historical data trend for Genomic Valley Biotech's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Valley Biotech Shiller PE Ratio Chart

Genomic Valley Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genomic Valley Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 768.35 626.31 440.43

Competitive Comparison of Genomic Valley Biotech's Shiller PE Ratio

For the Biotechnology subindustry, Genomic Valley Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Valley Biotech's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genomic Valley Biotech's Shiller PE Ratio falls into.


;
;

Genomic Valley Biotech Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genomic Valley Biotech's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=59.25/0.18
=329.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomic Valley Biotech's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Genomic Valley Biotech's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.51/158.3229*158.3229
=0.510

Current CPI (Dec. 2024) = 158.3229.

Genomic Valley Biotech Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.020 97.163 -0.033
201506 -0.070 99.841 -0.111
201509 -0.500 101.753 -0.778
201512 0.010 102.901 0.015
201603 -0.530 102.518 -0.818
201606 0.010 105.961 0.015
201609 -0.200 105.961 -0.299
201612 -0.120 105.196 -0.181
201703 0.090 105.196 0.135
201706 0.010 107.109 0.015
201709 0.010 109.021 0.015
201712 -0.060 109.404 -0.087
201803 0.140 109.786 0.202
201806 0.020 111.317 0.028
201809 0.030 115.142 0.041
201812 0.270 115.142 0.371
201903 0.430 118.202 0.576
201906 0.040 120.880 0.052
201909 0.070 123.175 0.090
201912 0.300 126.235 0.376
202003 0.530 124.705 0.673
202006 -0.440 127.000 -0.549
202009 -0.090 130.118 -0.110
202012 -0.040 130.889 -0.048
202103 -1.260 131.771 -1.514
202106 -0.360 134.084 -0.425
202109 -0.190 135.847 -0.221
202112 0.040 138.161 0.046
202203 0.480 138.822 0.547
202206 1.500 142.347 1.668
202209 0.200 144.661 0.219
202212 -2.790 145.763 -3.030
202303 3.210 146.865 3.460
202306 0.090 150.280 0.095
202309 0.080 151.492 0.084
202312 0.070 152.924 0.072
202403 -0.190 153.035 -0.197
202406 0.420 155.789 0.427
202409 0.480 157.882 0.481
202412 0.510 158.323 0.510

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genomic Valley Biotech  (BOM:539206) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Genomic Valley Biotech Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Genomic Valley Biotech's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Valley Biotech Business Description

Traded in Other Exchanges
N/A
Address
4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based company engaged in providing diagnostic services and related business services. It undertakes commercial production of plant tissue cultured plants of different species to feed the genetically improved plant market nationally as well as internationally. The group conducts research in the field of agriculture, plant tissue culture, medical biotechnology, SERI biotechnology, stem cell, food biotechnology, Drone technology, Poly House Construction, and others. It generates revenue from the sale of services.

Genomic Valley Biotech Headlines

No Headlines